indicated in combination with paclitaxel protein-bound for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells (IC) of any intensity covering ≥ 1% of the tumor area), as determined by an FDA-approved test
04-27-2021 01:00 PM - 04-29-2021 05:30 PM ET
Membership
JoinBenefitsRenew Your Membership
Privacy & Terms
About UsCode of Conduct